Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top 10 Correlated Stocks
TDOC
In the News
This beaten down Cathie Wood stock is a ‘buy': DA Davidson
Shares of Teladoc Health Inc (NYSE: TDOC) are in focus on Friday after a DA Davidson analyst said the beaten down telemedicine company is a “buy” at current levels.
3 People That Still Believe in Teladoc
Teladoc stock has fallen 88% since peaking last year. There are still investors that feel the time is right to buy or add to a position.
Why Teladoc Crawled Only Marginally Higher on Thursday
An analyst's positive new take on the company is mitigated by concerns about its recent performance.
Revisiting the Pandemic Winners: Time to Buy?
Those who flocked to the stay-at-home type of stocks during the pandemic were rewarded handsomely with considerable gains. In 2022, the story has been vividly different.
Cathie Wood Is Buying Teladoc (TDOC) Stock Up in a Frenzy
Shares of telehealth company Teladoc (NYSE: TDOC ) are in the spotlight, as Cathie Wood's Ark Invest has purchased shares of the company every day this week. From Aug. 8 to Aug. 10, Ark purchased 344,629 shares of TDOC stock.
Cathie Wood Is Doubling Down on Biotech Stocks DNA, NVTA, TDOC
It appears Cathie Wood is as long on biotech stocks as ever. The Ark Invest founder and manager has been buying up popular biotech companies like Ginkgo Bioworks (NYSE: DNA ), Invitae (NYSE: NVTA ) and Teladoc (NYSE: TDOC ) en masse this summer.
3 Supercharged Growth Stocks Down 88% to 93% That Billionaires Can't Stop Buying
Not even a bear market decline can faze billionaire money managers who are intent on owning innovative companies and future industry leaders.
Cathie Wood's Ark Invest Adds $4.5M In Teladoc Stock
Cathie Wood-led Ark Investment Management bought 129,800 shares of healthcare company Teladoc Health Inc (NYSE: TDOC), valued at over $4.5 million, based on Tuesday's closing price, via four of its exchange-traded funds (ETFs).
Why Teladoc Might Never Be a Warren Buffett Stock
The stock just isn't a fit for the billionaire investor's portfolio, and it's not for the reasons you might think.
Is There any Hope for Teladoc Stock in 2023?
Its recent performance leaves a lot to be desired.
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.21 | 6.35 | 7.7 | 12.09 | 22.46 | |
| Net income per share | -1.93 | -1.47 | -1.38 | -5.36 | -4.74 | |
| Operating cash flow per share | -0.62 | -0.07 | 0.42 | -0.59 | 2.14 | |
| Free cash flow per share | -0.72 | -0.2 | 0.26 | -0.88 | 1.44 | |
| Cash per share | 2.21 | 7.27 | 7.2 | 8.69 | 9.9 | |
| Book value per share | 10.08 | 15.39 | 14.11 | 175.49 | 177.28 | |
| Tangible book value per share | -1.79 | 0.43 | 0.59 | -7.94 | -4.07 | |
| Share holders equity per share | 10.08 | 15.39 | 14.11 | 175.49 | 177.28 | |
| Interest debt per share | 4.06 | 6.69 | 6.6 | 16.51 | 15.03 | |
| Market cap | 2.01B | 4.09B | 7.53B | 23.88B | 6.37B | |
| Enterprise value | 2.18B | 4.08B | 7.46B | 24.58B | 6.76B | |
| P/E ratio | -18.84 | -42.1 | -76.12 | -49.22 | -14.86 | |
| Price to sales ratio | 8.62 | 9.78 | 13.6 | 21.83 | 3.13 | |
| POCF ratio | -58.42 | -840.95 | 251.96 | -446.25 | 32.85 | |
| PFCF ratio | -50.36 | -308.06 | 396.74 | -300.17 | 48.99 | |
| P/B Ratio | 3.6 | 4.03 | 7.42 | 1.5 | 0.4 | |
| PTB ratio | 3.6 | 4.03 | 7.42 | 1.5 | 0.4 | |
| EV to sales | 9.33 | 9.76 | 13.48 | 22.47 | 3.32 | |
| Enterprise value over EBITDA | -30.91 | -115.67 | -210.11 | -56.19 | -79.82 | |
| EV to operating cash flow | -63.2 | -839.03 | 249.65 | -459.33 | 34.84 | |
| EV to free cash flow | -54.47 | -307.36 | 393.11 | -308.97 | 51.97 | |
| Earnings yield | -0.05 | -0.02 | -0.01 | -0.02 | -0.07 | |
| Free cash flow yield | -0.02 | 0 | 0 | 0 | 0.02 | |
| Debt to equity | 0.37 | 0.41 | 0.43 | 0.09 | 0.08 | |
| Debt to assets | 0.32 | 0.34 | 0.37 | 0.11 | 0.1 | |
| Net debt to EBITDA | -2.34 | 0.26 | 1.94 | -1.6 | -4.57 | |
| Current ratio | 3.87 | 8.53 | 6.52 | 3.19 | 3.7 | |
| Interest coverage | -4.31 | -2.71 | -2.77 | -8.37 | -3.31 | |
| Income quality | 0.32 | 0.05 | -0.3 | 0.11 | -0.45 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.35 | 0.28 | 0.3 | 0.46 | 0.22 | |
| Research and developement to revenue | 0.15 | 0.13 | 0.12 | 0.15 | 0.15 | |
| Intangibles to total assets | 0.8 | 0.64 | 0.61 | 0.94 | 0.93 | |
| Capex to operating cash flow | 0.16 | 1.73 | -0.36 | 0.49 | -0.33 | |
| Capex to revenue | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 | |
| Capex to depreciation | -0.29 | -0.24 | -0.24 | -0.33 | -0.29 | |
| Stock based compensation to revenue | 0.13 | 0.1 | 0.12 | 0.43 | 0.15 | |
| Graham number | 20.91 | 22.59 | 20.9 | 145.48 | 137.47 | |
| ROIC | -0.1 | -0.05 | -0.05 | -0.03 | -0.02 | |
| Return on tangible assets | -0.64 | -0.18 | -0.16 | -0.42 | -0.32 | |
| Graham Net | -2.22 | -0.07 | -0.4 | -10.27 | -6.96 | |
| Working capital | 115.91M | 470.3M | 497.82M | 726.96M | 894.43M | |
| Tangible asset value | -99.43M | 28.53M | 42.49M | -718.32M | -368.7M | |
| Net current asset value | -109.25M | 16.98M | -800K | -811.87M | -463.41M | |
| Invested capital | 0.37 | 0.41 | 0.44 | 0.09 | 0.08 | |
| Average receivables | 98.19M | 106.43M | 113.11M | 169.28M | 169.12M | |
| Average payables | 24.96M | 26.9M | 27.55M | 46.03M | 46.64M | |
| Average inventory | 0 | 0 | 0 | 56.5M | 64.79M | |
| Days sales outstanding | 42.39 | 38.05 | 37.57 | 56.48 | 30.34 | |
| Days payables outstanding | 23.01 | 22.03 | 17.96 | 42.99 | 26.53 | |
| Days of inventory on hand | 0 | 0 | 0 | 52.76 | 41.02 | |
| Receivables turnover | 8.61 | 9.59 | 9.72 | 6.46 | 12.03 | |
| Payables turnover | 15.87 | 16.57 | 20.33 | 8.49 | 13.76 | |
| Inventory turnover | 0 | 0 | 0 | 6.92 | 8.9 | |
| ROE | -0.19 | -0.1 | -0.1 | -0.03 | -0.03 | |
| Capex per share | -0.1 | -0.13 | -0.15 | -0.29 | -0.71 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.22 | 3.27 | 3.47 | 3.52 | 3.67 | |
| Net income per share | -0.86 | -0.53 | -0.07 | -41.58 | -19.22 | |
| Operating cash flow per share | 0.33 | 0.48 | 0.52 | -0.2 | 0.57 | |
| Free cash flow per share | 0.25 | 0.39 | 0.38 | -0.39 | 0.3 | |
| Cash per share | 5.04 | 5.18 | 5.6 | 5.23 | 5.48 | |
| Book value per share | 102.53 | 100.28 | 100.32 | 56.95 | 37.7 | |
| Tangible book value per share | -2.67 | -2.6 | -2.31 | -3.99 | -4 | |
| Share holders equity per share | 102.53 | 100.28 | 100.32 | 56.95 | 37.7 | |
| Interest debt per share | 8.14 | 8.07 | 8.12 | 9.91 | 9.8 | |
| Market cap | 25.95B | 20.22B | 14.69B | 11.58B | 5.36B | |
| Enterprise value | 26.42B | 20.66B | 15.07B | 12.33B | 6.06B | |
| P/E ratio | -48.48 | -59.93 | -334.23 | -0.43 | -0.43 | |
| Price to sales ratio | 51.58 | 38.76 | 26.5 | 20.48 | 9.05 | |
| POCF ratio | 496.97 | 263.97 | 176.5 | -364.73 | 57.96 | |
| PFCF ratio | 655.93 | 328.8 | 243.6 | -185.04 | 112.52 | |
| P/B Ratio | 1.62 | 1.26 | 0.92 | 1.27 | 0.88 | |
| PTB ratio | 1.62 | 1.26 | 0.92 | 1.27 | 0.88 | |
| EV to sales | 52.5 | 39.61 | 27.2 | 21.81 | 10.22 | |
| Enterprise value over EBITDA | -479.79 | -3.07K | 993.26 | -1.87 | -3.08K | |
| EV to operating cash flow | 505.91 | 269.76 | 181.15 | -388.34 | 65.49 | |
| EV to free cash flow | 667.72 | 336.01 | 250.02 | -197.01 | 127.14 | |
| Earnings yield | -0.01 | 0 | 0 | -0.58 | -0.58 | |
| Free cash flow yield | 0 | 0 | 0 | -0.01 | 0.01 | |
| Debt to equity | 0.08 | 0.08 | 0.08 | 0.17 | 0.26 | |
| Debt to assets | 0.09 | 0.09 | 0.1 | 0.18 | 0.25 | |
| Net debt to EBITDA | -8.48 | -65.88 | 25.48 | -0.11 | -354.39 | |
| Current ratio | 4 | 3.83 | 3.7 | 3.94 | 3.38 | |
| Interest coverage | -3.86 | -3.21 | -2.2 | -1.22K | -713.98 | |
| Income quality | -0.39 | -0.91 | -7.57 | 0 | -0.03 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.22 | 0.2 | 0.21 | 0.19 | 0.19 | |
| Research and developement to revenue | 0.16 | 0.15 | 0.13 | 0.15 | 0.14 | |
| Intangibles to total assets | 0.93 | 0.93 | 0.93 | 0.88 | 0.83 | |
| Capex to operating cash flow | -0.24 | -0.2 | -0.28 | 0.97 | -0.48 | |
| Capex to revenue | -0.03 | -0.03 | -0.04 | -0.05 | -0.08 | |
| Capex to depreciation | -0.23 | -0.27 | -0.4 | -0.49 | -0.71 | |
| Stock based compensation to revenue | 0.16 | 0.14 | 0.11 | 0.11 | 0.09 | |
| Graham number | 44.48 | 34.55 | 12.45 | 230.82 | 127.69 | |
| ROIC | 0 | 0 | 0 | -0.62 | -0.4 | |
| Return on tangible assets | -0.11 | -0.07 | -0.01 | -5.1 | -2.26 | |
| Graham Net | -4.23 | -4.24 | -3.94 | -5.7 | -5.89 | |
| Working capital | 828.61M | 855.21M | 894.43M | 901.36M | 885.79M | |
| Tangible asset value | -416.81M | -414.83M | -368.7M | -641.08M | -645.72M | |
| Net current asset value | -505.21M | -507.68M | -463.41M | -741.68M | -760.86M | |
| Invested capital | 0.08 | 0.08 | 0.08 | 0.17 | 0.26 | |
| Average receivables | 196.89M | 196.21M | 191.65M | 214.35M | 209.89M | |
| Average payables | 44.74M | 41.03M | 47.33M | 47.41M | 70.89M | |
| Average inventory | 63.82M | 63.8M | 71.87M | 70.65M | 65.46M | |
| Days sales outstanding | 32.1 | 30.72 | 27.44 | 34.12 | 31.21 | |
| Days payables outstanding | 23.63 | 18.45 | 24.31 | 22.82 | 46.55 | |
| Days of inventory on hand | 32 | 30.31 | 37.59 | 34 | 29.72 | |
| Receivables turnover | 2.8 | 2.93 | 3.28 | 2.64 | 2.88 | |
| Payables turnover | 3.81 | 4.88 | 3.7 | 3.94 | 1.93 | |
| Inventory turnover | 2.81 | 2.97 | 2.39 | 2.65 | 3.03 | |
| ROE | -0.01 | -0.01 | 0 | -0.73 | -0.51 | |
| Capex per share | -0.08 | -0.09 | -0.14 | -0.19 | -0.28 |
Company Profile
- Volume Average 6.2M
- Market Capitalization 6.06B
- Employee 4.34K
- CEO Mr. Jason Gorevic
- Headquarters Purchase,NEW YORK,US
- IPO Date 2015-07-01
-
Website
https://www.teladochealth.com 
Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
